Our Consultants and Partners have excellent academic backgrounds in biomedical and/or economic sciences combined with entrepreneurial spirit and extensive experience in world-leading health science companies. Target BioScience AG adheres strictly to the highest ethical standards and integrates client know-how.
Dr. Meinrad Good
Meinrad Good is founder and Managing Director of Target BioScience AG. He has extensive knowledge and experience in the pharmaceutical industry sector and has performed a number of consulting projects on a national and international level in scientific and regulatory affairs, quality assurance and business development. Meinrad Good has a PhD degree in Biochemistry and an advanced degree in General Management, both from the University of Zurich.
Dr. Maria Heimgartner
Maria Heimgartner has joined Target BioScience AG as a senior consultant in 2012 and serves now as a Principal Consultant in quality assurance, market access and business development. Prior to joining Target BioScience Maria Heimgartner has served as a General Manager for Genzyme Switzerland, a global biopharmaceutical company focused on rare diseases and multiple sclerosis. Maria Heimgartner brings over 15 years of pharmaceutical industry experience. Maria Heimgartner holds PhD degree from University of Munich and Bachelor of Science degree from University of Houston, Texas.
Dr. Jürgen Regenold
Jürgen Regenold has been on the Advisory Board of Target BioScience AG since 2006. He is the founder and CEO of the global regulatory affair company Dr. Regenold GmbH as well as the founder of global regulatory group regulanet®. Jürgen Regenold manages all aspects of the business from strategic product development to regulatory affairs and market access. Previously he served in management of pharmaceutical product development and regulatory affairs. Jürgen Regenold holds a PhD degree as a pharmacist from the Albert-Ludwigs-University of Freiburg.
Dr. Patrik Frei
Patrik Frei has been on the Advisory Board of Target BioScience AG since 2006. He is the founder and CEO of Venture Valuation AG, Switzerland. Since then he has been involved in over 350 valuations for investors as well as biotech, Pharma and medtech companies. He is also the Chairman of Ophthalmopharma, a Swiss based biotech ophthalmology company and a board member of Kleinkraftwerk Birseck AG (KKBN:Berne) a publicly quoted cleantech company. Patrik Frei graduated from the Business University of St. Gallen and completed his PhD thesis at the Swiss Federal Institute of Technology in Lausanne.
Heidi Matter has served on the management board at Target BioScience AG since 2005 to 2014 and is now a member of the Advisory Board. She has broad experience in major pharmaceutical companies as Vice President Marketing at Pfizer AG, Zürich, Pharma Distribution Manager at Bayer Schweiz AG, Managing Director at Cilag AG, Schaffhausen, Managing Director at Janssen-Cilag AG, Baar and as consultant with Matter Consult. Heidi Matter holds a degree in Pharmacy from Johann Wolfgang Goethe-University Frankfurt.
Dr. Tobias Ostler
Tobias is Senior Manager Scientific Affairs/Regulatory Sciences Biopharmaceuticals at our strategic partner Dr. Regenold GmbH and serves as an expert at Target BioScience AG since 2015 for Biopharmaceutical Drug development. As a former Head of Research at Thermo Fisher Scientific in Uppsala, Sweden and Head Immunology at IBR Inc. in Switzerland, he brings his extensive experience in industrial biopharmaceutical research and research. Tobias Ostler holds master degree in pharmaceutical chemistry and a PhD in Immunobiology.
Dr. Eric Bornand
Eric Bornand has joined Target BioScience AG as regulatory expert in 2003 and has the responsibility of an authorizied officer since 2009. Previously he was holding management positions at Opopharma AG, Merck, Sharp and Dohme Chibret AG, Bristol-Myers Squibb AG and as consultant with Consimpex AG. Eric received his PhD degree in Chemistry from the Federal Institute of Technology (ETH) in Zurich.